A Russian bioregulator tripeptide (Ala-Glu-Asp) marketed for cartilage and joint support — part of the Khavinson family, used in 10–20 day cycles. Khavinson-lineage data; no peer-reviewed Western RCT.
Cartalax is a short synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family — a group of Russian-developed peptides targeted at specific tissue types. Cartalax is tuned toward cartilage and connective tissue maintenance.
Like other Khavinson peptides (Epitalon, Testagen, Pinealon), it works at very low doses in short cycles rather than continuous use. The mechanism is gene-expression modulation at the tissue-specific level, not a direct hormonal or cytokine effect.
Not FDA approved. Sold in Russia as a биологически активная добавка (БАД, dietary supplement) — not as a registered pharmaceutical. Not WADA prohibited. Available as injectable powder or oral capsule.
Per Khavinson’s research, short peptides bind to specific DNA promoter regions, selectively influencing genes relevant to the tissue they’re targeted at. Cartalax is tuned toward chondrocyte (cartilage cell) gene expression.
Supports cartilage cell function, proteoglycan synthesis, and extracellular matrix maintenance — the cellular machinery that keeps joints functional.
Reduces inflammatory markers in joint tissues in animal studies — complementary to BPC-157 or systemic anti-inflammatories.
Research is primarily Russian and not widely replicated in Western trials. The Khavinson framework is well-documented within that research tradition; Western clinical evidence is limited.
| Benefit | Evidence |
|---|---|
| Joint comfort | Russian community/clinical use for osteoarthritis and joint pain. The only PubMed-indexed reference is a single review (PMID 37782637); no peer-reviewed RCT exists. |
| Cartilage support | Mechanistic claims (chondrocyte function, articular cartilage maintenance) trace to the Khavinson lineage; broad independent replication is limited. |
| Recovery from injury | Anecdotal community use adjunct to BPC-157. No clinical-trial evidence. |
| Age-related joint decline | Maintenance use in aging athletes; biomarker improvements reported in Khavinson-lineage cohort studies. Not validated outside that lineage. |
Expect subtle, accumulating effects over multiple cycles rather than dramatic acute changes.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNo human RCT of Cartalax has been published. The figures below reflect Khavinson-lineage and community-practice convention, not clinical-trial-validated dose-finding.
For joint-specific injuries, Cartalax (for cartilage) + BPC-157 (for tissue healing) is a reasonable stack. Run together during a 4–6 week acute protocol.
For injectable powder:
20 mg vial + 2 mL BAC water = 10 mg/mL = 10,000 mcg/mL
| Dose | Volume | Syringe Units |
|---|---|---|
| 100 mcg | 0.01 mL | 1 unit |
| 200 mcg | 0.02 mL | 2 units |
| 400 mcg | 0.04 mL | 4 units |
Low doses at small volumes — consider a more dilute reconstitution (5 mL BAC water for easier measurement). Oral capsules are pre-dosed and avoid measurement issues.
Pre-filled with a typical Cartalax setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Cartalax has an excellent reported safety profile in Russian clinical use. Side effects are rare and mild.
Looking for Cartalax? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeCartalax is a short synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, a group of Russian-developed peptides targeted at specific tissue types. Cartalax is tuned toward cartilage and connective tissue maintenance. Like other Khavinson peptides (Epitalon, Testagen, Pinealon), it works at very low doses in short cycles rather than continuous use.
Per Khavinson's research framework, short peptides bind to specific DNA promoter regions and selectively influence genes relevant to the tissue they're targeted at. Cartalax is tuned toward chondrocyte (cartilage cell) gene expression, supporting cartilage cell function, proteoglycan synthesis, and extracellular matrix maintenance. The mechanism is gene-expression modulation at the tissue-specific level, not a direct hormonal or cytokine effect.
Research is primarily Russian and not widely replicated in Western trials. The only PubMed-indexed reference for joint comfort is a single review (PMID 37782637); no peer-reviewed RCT exists. Mechanistic claims around chondrocyte function and articular cartilage maintenance trace to the Khavinson lineage; broad independent replication is limited. Expect subtle, accumulating effects over multiple cycles rather than dramatic acute changes.
No. Cartalax is not FDA approved. It is sold in Russia as a биологически активная добавка (BAD, dietary supplement), not as a registered pharmaceutical. It is not WADA prohibited. Available as injectable powder or oral capsule.
Community and Khavinson-convention dosing is 100 to 400 mcg/day for 10 to 20 days per cycle, run 2 to 4 cycles per year. Route is SubQ or oral capsule. No human RCT of Cartalax has been published, so these figures reflect convention rather than clinical-trial-validated dose-finding. For injectable powder, 20 mg vial + 2 mL bacteriostatic water gives 10 mg/mL; consider a more dilute reconstitution at low doses for easier measurement.
Cartalax has an excellent reported safety profile in Russian clinical use with rare and mild side effects: occasional injection site reactions (SubQ) or mild GI upset (oral). The more serious concern is oncology-adjacent: Cartalax-family short peptides enhance Ki-67 proliferation markers (PMIDs 26033601, 27259496), suppress caspase-3 mediated apoptosis, upregulate IGF1 gene expression 3.5 to 5.6 fold (PMID 32399807), and suppress p53 alongside p16 and p21 senescence markers (PMID 25946838). p53 is the central tumor-suppressor pathway, so personal or family history of cancer, hormone-sensitive tumors, and precancerous conditions all warrant oncologist oversight, not just currently active disease.
Different mechanisms, often stacked rather than substituted. Cartalax is positioned at chondrocyte gene expression for cartilage maintenance; BPC-157 is broader tissue healing. For joint-specific injuries the two are sometimes run together during a 4 to 6 week acute protocol. Cartalax has no peer-reviewed RCT for joints, so the case for stacking rests on mechanistic plausibility plus anecdote rather than head-to-head evidence.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.